- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Michael Kolodziej Discusses the Role of Commercial Payers in Value-Based Care
Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc., weighs in on the role of commercial payers in value-based care.
Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc., weighs in on the role of commercial payers in value-based care.
Transcript
Are commercial payers beginning to have a bigger presence in value-based care?
The issue with commercial payers is that they’re very interesting in doing things that are easy for them administratively. I don’t think they’re going to embrace [Oncology Care Model]. It’s just too complicated. It’s just too much work. I believe pathways are going to be—and you can certainly define pathways as value-based care. In fact, there is no definition of value-based care. There’s a broad spectrum of what constitutes value-based care, and pathways clearly exists within that spectrum.
I think payers will all adopt some sort of “value-based care program.” It might not be what the folks at OncoCloud consider value-based care, but it is by the strictest sense of the word a model of care.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
